NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

The original endpoints are still part of the revised SAP, so we’ll still see how those turned out. But if the treatment arm in the L trial shows an average or a medium of, for example only, 25 to 27 months, and that 15 to 20% of the treatment arm lived well past historical averages for that same percentage, wouldn’t you want this treatment to be given regulatory approval? Let patients and their doctors then decide if they want to give DcVax a try.

I think most of us would agree that for the most part, Optune is a tremendous waste of money for a GBM sufferer. The price hardly seems worth the quality of life loss. Yet you do not fret and post 24/7 about that topic, and in fact, when you do discuss it here, you don’t seem to be at all bothered by it in the least.

So I really can’t comprehend what it is that you are so hung up about.